Indications

Type 2 Diabetes Mellitus (NIDDM) (see Diabetes Mellitus)

• xxxx

---

Pharmacology

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist (see Glucagon-Like Peptide-1 Receptor Agonists)

• XXXX

---

Administration

• xxxx

---

Adverse Effects

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• xxxx